Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Gaetan Touyer"'
Autor:
Judith Sudhalter, Qiang Gao, Stephan Reiling, Isabelle Schreiber, Albane Courjaud, Jack Pollard, Eric Yang, Luc Bonnet, Joshua Murtie, Carlos Garcia-Echeverria, Matthieu Barrague, Fangxian Sun, Timothy He, Claudine Grepin, Monsif Bouaboula, Francisco Adrian, Bailin Zhang, Malvika Koundinya, M. Paola Castaldi, Gaetan Touyer, Bruno Lionne, Mark Munson, Richard Newcombe, Isabelle Menguy, Rosalia Arrebola, Stuart Licht, Yanjun Wang, Christopher Winter, Ronald Tomlinson, Patricia Gee, Hui Cao, Christelle Perrault, Stephanie Vougier, Aaron J. Morris, David Harper, Brigitte Benhamou, Hong Cheng, Ivan Cornella-Taracido, Daniel Simard
Publikováno v:
Cell Chemical Biology. 25:705-717.e11
Summary Activating KRAS mutations are major oncogenic drivers in multiple tumor types. Synthetic lethal screens have previously been used to identify targets critical for the survival of KRAS mutant cells, but their application to drug discovery has
Autor:
Gaetan Touyer, Véronique Jean-Baptiste, Dominique Lesuisse, Pierre Deprez, Edoardo Sarubbi, Eliane Mandine, Dominique Gofflo
Publikováno v:
Journal of Molecular Recognition. 14:254-260
Various SH2 competitive binding assays, based on different techniques, have been described in the literature to identify and characterize SH2 ligands. The consideration that most reported methods show experimental limitations associated with assay pa
Autor:
Brigitte Benhamou, Ivan Cornella-Taracido, Christelle Perrault, Stephanie Vougier, Bruno Lionne, Ronald Tomlinson, Francisco Adrian, Hui Cao, David P. Harper, Maria Paola Castaldi, Isabelle Schreiber, Jack Pollard, Malvika Koundinya, Monsif Bouaboula, Albane Courjaud, Gaetan Touyer, Rosalia Arrebola, Luc Bonnet, Aaron J. Morris, Daniel Simard, Stephan Reiling, Judith Sudhalter, Carlos Garcia-Echeverria, Claudine Grepin, Isabelle Menguy
Publikováno v:
Cancer Research. 73:2243-2243
Activating KRAS mutations are oncogenic and prevalent in multiple tumor types, being found in as high as 90% of pancreatic carcinomas and 50% of colorectal carcinomas. In spite of its attractiveness for therapeutic intervention to date no KRAS-target
Publikováno v:
International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology. 14:iii
Novel radioactive DELTA 4,9,11-estratrienes marked with iodine 125 or 131 having the formula I wherein R is selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms and acyl of an organic carboxylic acid of 2 to 12 carbon atoms, R
Publikováno v:
International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology. 14:ii
Novel radioactive estradienes labelled with iodine of the formula ##STR1## in the form of their syn or anti isomers or mixtures thereof wherein the wavy line indicates anti or syn position, R is selected from the group consisting of hydrogen, alkyl o